Form 4 Filing for Dyne Therapeutics, Inc.

This filing details transactions by Jason P. Rhodes, a director at Dyne Therapeutics, Inc. (DYN), involving the sale of common stock on July 6th and 7th, 2026. These sales were executed under a Rule 10b5-1 trading plan. On July 6th, a total of 480,230 shares were sold across multiple transactions at a weighted average price of $22.79, with individual prices ranging from $22.4163 to $23.25. On July 7th, further sales occurred, with 265,268 shares sold at weighted average prices of $23.17 and $23.62, and prices ranging from $23.46 to $23.8628. An additional 5,000 shares were sold on the same day at a weighted average price of $23.61. The shares sold were held indirectly through various Atlas Venture Funds, with Rhodes P. disclaiming beneficial ownership except to the extent of his pecuniary interest. Post-transaction shareholdings vary across the different funds but indicate a significant reduction in holdings.